Transformative new scientific information capabilities
combine an unparalleled collection of curated science data with
advanced predictive models to accelerate early-stage drug discovery
innovation
COLUMBUS, Ohio, May 21, 2024
/PRNewswire/ -- Today, CAS, a division of the American
Chemical Society specializing in scientific knowledge management,
announced the launch of the CAS BioFinder Discovery Platform™, a
comprehensive life sciences offering that will reveal novel
insights through unprecedented data connections. The new offering
provides drug discovery scientists with the ability to explore
known and predicted data, find answers to their questions quickly
and reliably, and accelerate the pre-clinical drug discovery
process.
"As the volume and complexity of scientific content grows,
drug discovery scientists spend too much time combing through
data," said Manuel Guzman,
President, CAS. "R&D organizations that partner with CAS
will be empowered to navigate the overwhelming amount of scientific
information and get the insights they need to drive innovative,
life-saving drugs to market faster."
The CAS BioFinder Discovery Platform taps into science content
through the CAS Content Collection™, which includes the world's
most comprehensive, highly structured, human-curated scientific
data. In addition to connecting biological sequences,
structure-activity relationship data, ADME-measurement, and
toxicity to its substance collection, CAS more recently
incorporated biomarker data linked to diseases and drugs. CAS
leveraged Chemotargets CLARITY® as the technological
foundation for the CAS BioFinder™ predictive capabilities and
analytics.
Pairing this wealth of scientific knowledge with proprietary
AI-powered technology and an intuitive, visual interface, the CAS
BioFinder Discovery Platform is built to serve drug discovery
scientists in their research just like CAS SciFinder®
has served chemists and related scientists for decades.
Through the CAS BioFinder Discovery Platform, users can explore
empirical data and run predictive models to understand the likely
effects of novel molecules. The new platform also includes API
access to bioactivity and biomarker data that scientists will be
able to process using their in-house models. Over time, users will
benefit from fully integrated innovation capabilities that span
their spectrum of data, research, and workflow needs.
To ensure that the CAS BioFinder Discovery Platform addresses
drug discovery scientists' most salient pain points, last year CAS
assembled a Life Sciences Industry Advisory Board composed of
global thought leaders from commercial, academic, and government
organizations who have guided the organization's journey into life
sciences. An early version of CAS BioFinder was also shared with
several industry partners whose feedback has helped make the
solution strong from the start.
"Our mission with the CAS BioFinder Discovery Platform is to
help drug discovery scientists in early stages advance their
research more efficiently and confidently so that they can solve
the types of therapeutic problems that made them excited to start
their research in the first place," said Dr. Michael Dennis, Chief Scientific Officer, CAS.
"The solution enables scientists to find, compile, understand,
and trust the scientific content they need, to use it seamlessly to
run analytical and predictive models, and to discover the answers
and insights to ultimately propel their research, so the world
doesn't have to wait for the next drug discovery
breakthrough."
The CAS BioFinder Discovery Platform will continue to evolve and
be enhanced to meet the needs of drug discovery scientists.
Learn more about the CAS BioFinder Discovery Platform at
https://www.cas.org/solutions/biofinder-discovery-platform.
About CAS
CAS connects the world's scientific knowledge to accelerate
breakthroughs that improve lives. We empower global innovators to
efficiently navigate today's complex data landscape and make
confident decisions in each phase of the innovation journey. As a
specialist in scientific knowledge management, our team builds the
largest authoritative collection of human-curated scientific data
in the world and provides essential information solutions,
services, and expertise. Scientists, patent professionals, and
business leaders across industries rely on CAS to help them uncover
opportunities, mitigate risks, and unlock shared knowledge so they
can get from inspiration to innovation faster. CAS is a division of
the American Chemical Society. Connect with us at cas.org.
Photo -
https://mma.prnewswire.com/media/2416010/CAS_BioFinder.jpg
Logo
- https://mma.prnewswire.com/media/1729161/4713097/CAS_Logo.jpg
View original content to download
multimedia:https://www.prnewswire.com/news-releases/new-cas-biofinder-discovery-platform-empowers-drug-discovery-scientists-to-reveal-insights-drive-innovation-and-save-time-302149202.html
SOURCE CAS